BACKGROUND: Oropharyngeal squamous carcinoma (OPSC) continues to increase in incidence secondary to human papillomavirus (HPV) infection. Despite the good overall prognosis for these patients, treatment with chemoradiation is associated with morbidity and treatment failure. Better predictors for disease outcome are needed to guide de-intensification regimens. We hypothesized that estrogen receptor α (ERα), a prognostic biomarker in oncology with therapeutic implications, might have similar utility in OPSC. METHODS: To investigate associations among ERα and demographics, HPV status, and survival, we analyzed ERα mRNA expression of head and neck squamous carcinomas (HNSC) from The Cancer Genome Atlas (TCGA) and immunohistochemistry (IHC) of pretreatment biopsy specimens from an independent group of 215 OPSC patients subsequently treated with primary chemoradiation (OPSC-CR). Associations among variables were evaluated with Fisher exact tests and logistic regression; associations with survival were evaluated with log-rank tests and Cox proportional hazards regression. RESULTS: Among 515 patients in TCGA, ERα mRNA expression was highest in HPV-positive OPSC. High ERα mRNA expression was associated with improved survival among those receiving chemoradiation (hazard ratio adjusted for HPV status = 0.44, 95% confidence interval = 0.21 to 0.92). In OPSC-CR, ERα was positive by IHC in 51.6% of tumors and was associated with improved overall, disease-specific, progression-free, and relapse-free survival (log-rank tests: P < .001, P < .001, P = .002, P = .003, respectively); statistically significant associations of ERα positivity with improved survival were maintained after adjusting for clinical risk factors including HPV status. CONCLUSION: In two independent cohorts, ERα is a potential biomarker for improved survival that also may represent a therapeutic target in OPSC.
BACKGROUND: Oropharyngeal squamous carcinoma (OPSC) continues to increase in incidence secondary to human papillomavirus (HPV) infection. Despite the good overall prognosis for these patients, treatment with chemoradiation is associated with morbidity and treatment failure. Better predictors for disease outcome are needed to guide de-intensification regimens. We hypothesized that estrogen receptor α (ERα), a prognostic biomarker in oncology with therapeutic implications, might have similar utility in OPSC. METHODS: To investigate associations among ERα and demographics, HPV status, and survival, we analyzed ERα mRNA expression of head and neck squamous carcinomas (HNSC) from The Cancer Genome Atlas (TCGA) and immunohistochemistry (IHC) of pretreatment biopsy specimens from an independent group of 215 OPSC patients subsequently treated with primary chemoradiation (OPSC-CR). Associations among variables were evaluated with Fisher exact tests and logistic regression; associations with survival were evaluated with log-rank tests and Cox proportional hazards regression. RESULTS: Among 515 patients in TCGA, ERα mRNA expression was highest in HPV-positive OPSC. High ERα mRNA expression was associated with improved survival among those receiving chemoradiation (hazard ratio adjusted for HPV status = 0.44, 95% confidence interval = 0.21 to 0.92). In OPSC-CR, ERα was positive by IHC in 51.6% of tumors and was associated with improved overall, disease-specific, progression-free, and relapse-free survival (log-rank tests: P < .001, P < .001, P = .002, P = .003, respectively); statistically significant associations of ERα positivity with improved survival were maintained after adjusting for clinical risk factors including HPV status. CONCLUSION: In two independent cohorts, ERα is a potential biomarker for improved survival that also may represent a therapeutic target in OPSC.
Authors: Hareesh B Nair; Roopa Luthra; Nameer Kirma; Ya-Guang Liu; Lisa Flowers; Dean Evans; Rajeshwar Rao Tekmal Journal: Cancer Res Date: 2005-12-01 Impact factor: 12.701
Authors: M L Gillison; W M Koch; R B Capone; M Spafford; W H Westra; L Wu; M L Zahurak; R W Daniel; M Viglione; D E Symer; K V Shah; D Sidransky Journal: J Natl Cancer Inst Date: 2000-05-03 Impact factor: 13.506
Authors: Cornelius H L Kürten; Aditi Kulkarni; Lazar Vujanovic; Anthony R Cillo; Patricia M Santos; Anna K Roble; Sayali Onkar; Carly Reeder; Stephan Lang; Xueer Chen; Umamaheswar Duvvuri; Seungwon Kim; Angen Liu; Tracy Tabib; Robert Lafyatis; Jian Feng; Shou-Jiang Gao; Tullia C Bruno; Dario A A Vignali; Xinghua Lu; Riyue Bao; Robert L Ferris Journal: Nat Commun Date: 2021-12-17 Impact factor: 14.919
Authors: Virginia Drake; Elaine Bigelow; Carole Fakhry; Melina Windon; Lisa M Rooper; Patrick Ha; Brett Miles; Christine Gourin; Rajarsi Mandal; Wojciech Mydlarz; Nyall London; Peter S Vosler; Siddhartha Yavvari; Tanya Troy; Tim Waterboer; David W Eisele; Gypsyamber D'Souza Journal: Oral Oncol Date: 2021-07-22 Impact factor: 5.972
Authors: Soohyeon Kwon; Soon-Hyun Ahn; Woo-Jin Jeong; Young Ho Jung; Yun Jung Bae; Jin Ho Paik; Jin-Haeng Chung; Hyojin Kim Journal: J Transl Med Date: 2020-06-16 Impact factor: 5.531
Authors: Zongtai Qi; Yating Liu; Michael Mints; Riley Mullins; Reilly Sample; Travis Law; Thomas Barrett; Angela L Mazul; Ryan S Jackson; Stephen Y Kang; Patrik Pipkorn; Anuraag S Parikh; Itay Tirosh; Joseph Dougherty; Sidharth V Puram Journal: Cancers (Basel) Date: 2021-03-11 Impact factor: 6.575